DK3098225T3 - NITROGEN CONTAINING MACROCYCLIC CONJUGATES AS RADIO PHARMACY - Google Patents

NITROGEN CONTAINING MACROCYCLIC CONJUGATES AS RADIO PHARMACY Download PDF

Info

Publication number
DK3098225T3
DK3098225T3 DK16172324.2T DK16172324T DK3098225T3 DK 3098225 T3 DK3098225 T3 DK 3098225T3 DK 16172324 T DK16172324 T DK 16172324T DK 3098225 T3 DK3098225 T3 DK 3098225T3
Authority
DK
Denmark
Prior art keywords
group
optionally substituted
molecular recognition
formula
compound
Prior art date
Application number
DK16172324.2T
Other languages
Danish (da)
English (en)
Inventor
Paul Stephen Donnelly
Michelle Therese Ma
Denis Bernard Scanlon
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008906239A external-priority patent/AU2008906239A0/en
Application filed by Univ Melbourne filed Critical Univ Melbourne
Application granted granted Critical
Publication of DK3098225T3 publication Critical patent/DK3098225T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16172324.2T 2008-12-02 2009-12-02 NITROGEN CONTAINING MACROCYCLIC CONJUGATES AS RADIO PHARMACY DK3098225T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008906239A AU2008906239A0 (en) 2008-12-02 Radiopharmaceuticals
EP09829884.7A EP2370447B1 (en) 2008-12-02 2009-12-02 Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

Publications (1)

Publication Number Publication Date
DK3098225T3 true DK3098225T3 (en) 2019-03-25

Family

ID=42232814

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16172324.2T DK3098225T3 (en) 2008-12-02 2009-12-02 NITROGEN CONTAINING MACROCYCLIC CONJUGATES AS RADIO PHARMACY

Country Status (9)

Country Link
US (8) US9701694B2 (enExample)
EP (2) EP2370447B1 (enExample)
JP (2) JP2012510477A (enExample)
CN (1) CN102300866B (enExample)
AU (1) AU2009322081C1 (enExample)
CA (1) CA2745495C (enExample)
DK (1) DK3098225T3 (enExample)
ES (1) ES2712881T3 (enExample)
WO (1) WO2010063069A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6207504B2 (ja) 2011-07-07 2017-10-04 オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション クリプテート化合物
WO2013082655A1 (en) * 2011-12-06 2013-06-13 The University Of Melbourne Functionalisation of cage amine ligands for metallo-radiopharmaceuticals
DK2788353T3 (da) * 2011-12-06 2022-08-15 Clarity Pharmaceuticals Ltd Bur-aminligander til metallo-radiofarmaceutika
US9422286B2 (en) 2014-01-27 2016-08-23 Washington University Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
WO2018081860A1 (en) * 2016-11-04 2018-05-11 Clarity Pharmaceuticals Pty Ltd Formulations for radiotherapy and diagnostic imaging
CA3066525A1 (en) 2017-06-06 2018-12-13 The University Of Melbourne Radiopharmaceuticals, radioimaging agents, and uses thereof
AU2019251769A1 (en) * 2018-04-11 2020-10-15 Clarity Pharmaceuticals Limited Formulations and kits for radiotherapy and diagnostic imaging
CN111989324A (zh) * 2018-04-11 2020-11-24 墨尔本大学 靶向化合物及其生产方法
EP3976025A4 (en) * 2019-05-24 2023-05-17 Clarity Pharmaceuticals Limited PSMA IMAGING AGENT FORMULATIONS
WO2021087568A1 (en) * 2019-11-08 2021-05-14 The University Of Queensland Radiolabelled targeting ligands
WO2021150258A1 (en) * 2020-01-26 2021-07-29 Mainline Biosciences Llc Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
JP7894086B2 (ja) * 2020-05-06 2026-07-23 コーネル ユニヴァーシティー 銅含有セラグノスティック化合物及びその使用の方法
EP4196175A4 (en) * 2020-08-14 2025-07-30 Clarity Pharmaceuticals Ltd RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
AU2023322240A1 (en) * 2022-08-11 2025-02-20 Clarity Pharmaceuticals Limited Dimeric radiopharmaceuticals, compositions thereof and uses thereof
CN116589508A (zh) * 2023-05-16 2023-08-15 洛阳师范学院 一种基于半夹心铑构筑单元的矩形分子大环化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001719A1 (en) 1977-10-26 1979-05-02 The Australian National University Metal complexes, their preparation and production of hydrogen peroxide therewith
CN1033030C (zh) * 1988-06-24 1996-10-16 唐化学原料公司 大环双官能螯合剂及其配合物和抗体共轭物的制备方法
US5245055A (en) * 1990-12-18 1993-09-14 E. R. Squibb & Sons, Inc. Process for preparing a cis oxabicyclo olefinic acid and ester from an oxabicyclo pyranol
JPH04244085A (ja) * 1990-12-21 1992-09-01 Doujin Kagaku Kenkyusho:Kk 蛍光性化合物、錯体、試薬および該試薬を用いる特異的結合アッセイ
CZ307096A3 (en) * 1994-04-22 1997-09-17 Monsanto Co Methods of video analysis by making use of metal complexes of nitrogen-containing macrocyclic ligands
WO1995031202A1 (en) * 1994-05-17 1995-11-23 Commonwealth Scientific And Industrial Research Organisation Cage compounds, processes for their preparation and their use as antiviral agents
AUPP803899A0 (en) * 1999-01-05 1999-01-28 Australian National University, The Cryptate compounds and methods for diagnosis and therapy.
US6107326A (en) 1999-04-12 2000-08-22 Cytopharm, Inc. Porphycenes for treatment of microbial populations
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
EP1331012A1 (en) * 2002-01-29 2003-07-30 BRACCO IMAGING S.p.A. Responsive paramagnetic MRI contrast agents
FI20031528A0 (fi) * 2003-10-17 2003-10-17 Ctt Cancer Targeting Tech Oy Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
WO2008147481A1 (en) * 2007-02-09 2008-12-04 Northeastern University Precision-guided nanoparticle systems for drug delivery

Also Published As

Publication number Publication date
US20170267699A1 (en) 2017-09-21
EP3098225A1 (en) 2016-11-30
US20240190897A1 (en) 2024-06-13
CN102300866B (zh) 2015-08-26
US20200115391A1 (en) 2020-04-16
US20210363161A1 (en) 2021-11-25
AU2009322081B2 (en) 2016-05-26
ES2712881T3 (es) 2019-05-16
US20110293517A1 (en) 2011-12-01
EP2370447B1 (en) 2016-07-27
CA2745495A1 (en) 2010-06-10
AU2009322081C1 (en) 2016-09-01
US12565506B2 (en) 2026-03-03
EP3098225B1 (en) 2018-11-28
JP5981580B2 (ja) 2016-08-31
JP2012510477A (ja) 2012-05-10
US9701694B2 (en) 2017-07-11
CN102300866A (zh) 2011-12-28
US20170267698A1 (en) 2017-09-21
EP2370447A4 (en) 2013-08-14
JP2015145367A (ja) 2015-08-13
AU2009322081A1 (en) 2011-07-21
US20260226078A1 (en) 2026-08-06
US11905301B2 (en) 2024-02-20
US20190225625A1 (en) 2019-07-25
CA2745495C (en) 2017-07-18
US10870664B2 (en) 2020-12-22
WO2010063069A1 (en) 2010-06-10
US10544164B2 (en) 2020-01-28
US11111254B2 (en) 2021-09-07
US10301326B2 (en) 2019-05-28
EP2370447A1 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
US12565506B2 (en) Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
EP2788353B1 (en) Cage amine ligands for metallo-radiopharmaceuticals
DK2788354T3 (en) FUNCTIONALIZATION OF CAGE AMINIGANDS FOR METALLO-RADIOPHARMACEUTICAL AGENTS
EP4196175A1 (en) Radiopharmaceuticals, uses thereof, and methods for the production thereof
HK40080888A (en) Cage amine ligands for metallo-radiopharmaceuticals